C
8.37
-0.03 (-0.36%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Corvus Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.25 |
|
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.83% |
| 机构持股比例 | 48.27% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Adams Street Partners Llc | 30 Sep 2025 | 3,275,616 |
| Vivo Capital, Llc | 30 Sep 2025 | 2,234,566 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 407,709 |
| 52周波幅 | ||
| 中 | 16.00 (91.16%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 13 Oct 2025 | 16.00 (91.16%) | 购买 | 7.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合